Primary Testicular Lymphoma with Central Nervous System Relapse Was Successfully Treated by a Chemo-Free Regimen: A Case Report and Literature Review

References

• Cheah CY, Wirth A, Seymour JF. Primary testicular lymphoma. Blood. 2014;123(4):486–493. doi:10.1182/blood-2013-10-53065924282217
   PubMed Web of Science ®Google Scholar
• Xu H, Yao F. Primary testicular lymphoma: a SEER analysis of 1,169 cases. Oncol Lett. 2019;17(3):3113–3124. doi:10.3892/ol.2019.995330867741
   PubMed Web of Science ®Google Scholar
• Deng L, Xu-Monette ZY, Loghavi S, et al. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016;30(2):361–372. doi:10.1038/leu.2015.23726308769
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20–27. doi:10.1200/JCO.2003.11.14112506165
   PubMed Web of Science ®Google Scholar
• Ma RZ, Tian L, Tao LY, et al. The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience. Asian J Androl. 2018;20(6):615–620. doi:10.4103/aja.aja_73_1830246707
   PubMed Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922–926. doi:10.1038/nm.388426193343
   PubMed Web of Science ®Google Scholar
• Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–1029. doi:10.1158/2159-8290.CD-17-061328619981
   PubMed Web of Science ®Google Scholar
• Kraan W, Horlings HM, van Keimpema M, et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J. 2013;3:e139. doi:10.1038/bcj.2013.2824013661
   PubMed Web of Science ®Google Scholar
• Oishi N, Kondo T, Nakazawa T, et al. High prevalence of the MYD88 mutation in testicular lymphoma: immunohistochemical and genetic analyses. Pathol Int. 2015;65(10):528–535. doi:10.1111/pin.1233626388135
   PubMed Web of Science ®Google Scholar
• Zouhair A, Weber D, Belkacemi Y, et al. Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys. 2002;52(3):652–656. doi:10.1016/s0360-3016(01)02647-511849786
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Ridell B, Wedel H, Norrby K, Sender Baum M, Ekman T. Testicular lymphoma–a retrospective, population-based, clinical and immunohistochemical study. Acta Oncol. 2004;43(8):758–765. doi:10.1080/0284186041000285115764222
   PubMed Web of Science ®Google Scholar
• Linassier C, Desablens B, Lefrancq T, et al. Stage I-IIE primary non-Hodgkin’s lymphoma of the testis: results of a prospective trial by the GOELAMS Study Group. Clin Lymphoma. 2002;3(3):167–172. doi:10.3816/clm.2002.n.02312521394
   PubMedGoogle Scholar
• Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS. Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience. Leuk Lymphoma. 2010;51(7):1217–1224. doi:10.3109/1042819100379335820443676
   PubMed Web of Science ®Google Scholar
• Aviles A, Nambo MJ, Cleto S, Neri N, Huerta-Guzman J. Rituximab and dose-dense chemotherapy in primary testicular lymphoma. Clin Lymphoma Myeloma. 2009;9(5):386–389. doi:10.3816/CLM.2009.n.07519858059
   PubMedGoogle Scholar
• Cao B, Ji DM, Zhou XY, et al. A clinical analysis of primary testicular diffuse large B-cell lymphoma in China. Hematology. 2011;16(5):291–297. doi:10.1179/102453311X1308564468022121902893
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international Phase II trial. J Clin Oncol. 2011;29(20):2766–2772. doi:10.1200/JCO.2010.31.418721646602
   PubMed Web of Science ®Google Scholar
• Jordanova ES, Riemersma SA, Philippo K, Schuuring E, Kluin PM. Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system. Int J Cancer. 2003;103(3):393–398. doi:10.1002/ijc.1082412471623
   PubMed Web of Science ®Google Scholar
• Kim J, Yoon DH, Park I, et al. Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience. Blood Res. 2014;49(3):170–176. doi:10.5045/br.2014.49.3.17025325036
   PubMedGoogle Scholar
• Kridel R, Telio D, Villa D, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017;176(2):210–221. doi:10.1111/bjh.1439227739058
   PubMed Web of Science ®Google Scholar
• Zhou, Bao C, Ye X, et al. Clinical and histological features of primary testicular diffuse large B-cell lymphoma: a single center experience in China. Oncotarget. 2017;8(68):112384–112389. doi:10.18632/oncotarget.1973629348832
   PubMedGoogle Scholar
• Jovanovic MP, Mihaljevic B, Jovanovic P, et al. Clinicopathological and fluorescence in situ hibridisation analysis of primary testicular diffuse large B-cell lymphoma: a single-centre case series. Pol J Pathol. 2018;69(2):136–142. doi:10.5114/pjp.2018.7669730351860
   PubMed Web of Science ®Google Scholar
• Liu YZ, Luo P, Liu C, et al. Prognostic significance of LDH ratio in serum/cerebral spinal fluid of patients with primary testicular diffuse large B-cell lymphoma. Onco Targets Ther. 2019;12:10469–10475. doi:10.2147/OTT.S22874631819527
   PubMed Web of Science ®Google Scholar
• Chen B, Cao DH, Lai L, et al. Adult primary testicular lymphoma: clinical features and survival in a series of patients treated at a high-volume institution in China. BMC Cancer. 2020;20(1):220. doi:10.1186/s12885-020-6711-032171265
   PubMed Web of Science ®Google Scholar
• Caumont F, Porter C, DeBerg H, Burns J, Frankel J, Flores JP. Combined chemotherapy and radiotherapy improves survival in 1897 testicular Lymphoma patients from a contemporary cohort. Urol Oncol. 2020;38(7):641e1–641e8. doi:10.1016/j.urolonc.2020.02.027
   Web of Science ®Google Scholar
• Mannisto S, Vahamurto P, Pollari M, et al. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma. Eur J Cancer. 2019;115:27–36. doi:10.1016/j.ejca.2019.04.00431082690
   PubMed Web of Science ®Google Scholar
• Huang Y, Shi X, Zhong P, et al. De Novo testicular extranodal NK/T-cell lymphoma: a clinicopathologic study of 21 cases with review of additional 18 cases in the literature. Am J Surg Pathol. 2019;43(4):549–558. doi:10.1097/PAS.000000000000121030589649
   PubMed Web of Science ®Google Scholar
• Lones MA, Raphael M, McCarthy K, et al. Primary follicular lymphoma of the testis in children and adolescents. J Pediatr Hematol Oncol. 2012;34(1):68–71. doi:10.1097/MPH.0b013e31820e463622215099
   PubMed Web of Science ®Google Scholar
• Liang DN, Yang ZR, Wang WY, et al. Extranodal nasal type natural killer/T-cell lymphoma of testis: report of seven cases with review of literature. Leuk Lymphoma. 2012;53(6):1117–1123. doi:10.3109/10428194.2011.64520922132873
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Koike H, Esa A. Plasmablastic lymphoma of the right testis. Int J Urol. 2011;18(1):85–86. doi:10.1111/j.1442-2042.2010.02669.x21073544
   PubMed Web of Science ®Google Scholar
• Licci S, Morelli L, Covello R. Primary mantle cell lymphoma of the testis. Ann Hematol. 2011;90(4):483–484. doi:10.1007/s00277-010-1049-320714722
   PubMed Web of Science ®Google Scholar
• Kraan W, van Keimpema M, Horlings HM, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia. 2014;28(3):719–720. doi:10.1038/leu.2013.34824253023
   PubMed Web of Science ®Google Scholar
• Chapuy B, Roemer MG, Stewart C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–881. doi:10.1182/blood-2015-10-67323626702065
   PubMed Web of Science ®Google Scholar
• Wang X, Xu X, Cai W, et al. TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients. Biomark Res. 2020;8:10. doi:10.1186/s40364-020-00189-132322395
   PubMed Web of Science ®Google Scholar
• Menter T, Ernst M, Drachneris J, et al. Phenotype profiling of primary testicular diffuse large B-cell lymphomas. Hematol Oncol. 2014;32(2):72–81. doi:10.1002/hon.209023949965
   PubMed Web of Science ®Google Scholar
• Twa DDW, Lee DG, Tan KL, et al. Genomic predictors of central nervous system relapse in primary testicular diffuse large B-cell lymphoma. Blood. 2021;137(9):1256–1259. doi:10.1182/blood.202000633832967007
   PubMed Web of Science ®Google Scholar
• Zhu D, Zhu J, Yu W, et al. Expression of programmed cell death-ligand 1 in primary testicular diffuse large B cell lymphoma: a retrospective study. Oncol Lett. 2019;18(3):2670–2676. doi:10.3892/ol.2019.1059531452749
   PubMed Web of Science ®Google Scholar
• Riemersma SA, Oudejans JJ, Vonk MJ, et al. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis. J Pathol. 2005;206(3):328–336. doi:10.1002/path.178315887291
   PubMed Web of Science ®Google Scholar
• Booman M, Douwes J, Legdeur MC, van Baarlen J, Schuuring E, Kluin P. From brain to testis: immune escape and clonal selection in a B cell lymphoma with selective outgrowth in two immune sanctuaries [correction of sanctuariesy]. Haematologica. 2007;92(6):e69–71. doi:10.3324/haematol.1142117650453
   PubMed Web of Science ®Google Scholar
• Brouwer CL, Wiesendanger EM, van der Hulst PC, van Imhoff GW, Langendijk JA, Beijert M. Scrotal irradiation in primary testicular lymphoma: review of the literature and in silico planning comparative study. Int J Radiat Oncol Biol Phys. 2013;85(2):298–308. doi:10.1016/j.ijrobp.2012.06.01922836054
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Huerta-Guzman J, Perez F, Fernandez R. Testicular lymphoma: organ-specific treatment did not improve outcome. Oncology. 2004;67(3–4):211–214. doi:10.1159/00008131915557780
   PubMed Web of Science ®Google Scholar
• Pollari M, Bruck O, Pellinen T, et al. PD-L1(+) tumor-associated macrophages and PD-1(+) tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica. 2018;103(11):1908–1914. doi:10.3324/haematol.2018.19719430026337
   PubMed Web of Science ®Google Scholar
• Leivonen SK, Pollari M, Bruck O, et al. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. Haematologica. 2019;104(2):338–346. doi:10.3324/haematol.2018.20010530237271
   PubMed Web of Science ®Google Scholar
• Chen YP, Ke LF, Lu JP, et al. Prevalence and clinical significance of oncogenic CD79B and MYD88 mutations in primary testicular diffuse large b-cell lymphoma: a retrospective study in China. Onco Targets Ther. 2019;12:10165–10175. doi:10.2147/OTT.S22218932063711
   PubMed Web of Science ®Google Scholar
• Bernasconi B, Uccella S, Martin V, et al. Gene translocations in testicular lymphomas. Leuk Lymphoma. 2014;55(6):1410–1412. doi:10.3109/10428194.2013.83405523952247
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3073. doi:10.1182/blood-2017-01-76420928356247
   PubMed Web of Science ®Google Scholar
• Ping N, Qu C, Bai L, et al. Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression. Leuk Lymphoma. 2019;60(11):2814–2816. doi:10.1080/10428194.2019.160550731088197
   PubMed Web of Science ®Google Scholar
• Bernard S, Goldwirt L, Amorim S, et al. Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse. Blood. 2015;126(14):1695–1698. doi:10.1182/blood-2015-05-64783426239089
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol. 2011;29(20):e595–7. doi:10.1200/JCO.2011.34.725221519022
   PubMed Web of Science ®Google Scholar